Abstract No US Food and Drug Administration-or European Medicines Agency-approved
therapies exist for bleeding due to hereditary hemorrhagic telangiectasia (HHT), the second …

Background Bevacizumab—a humanized monoclonal antibody—has been widely used to
treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has …

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare
multisystem vascular disorder that causes chronic gastrointestinal bleeding, epistaxis, and …

Dear Editor, Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
vascular disorder characterized by a multisystem vascular dyscrasia leading to severe and …

Introduction Systemic bevacizumab is a novel targeted therapy for severe epistaxis and
chronic gastrointestinal bleeding in hereditary haemorrhagic telangiectasia (HHT), but …

Management of bleeding in hereditary hemorrhagic telangiectasia (HHT), the second most
common hereditary bleeding disorder in the world, is currently undergoing a paradigm shift …

In this issue of JIM, Dupuis-Girod et al. present the results of a French phase 2, randomized,
placebo-controlled trial of systemic bevacizumab to treat bleeding in 24 patients with …

Background For extreme hereditary hemorrhagic telangiectasia (HHT) disease, treatments
such as intravenous bevacizumab are often utilized. However, whether its efficacy is similar …

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that leads
to mucocutaneous telangiectasias, epistaxis, and gastrointestinal bleeding. Depending on …

Background Hereditary haemorrhagic telangiectasia (HHT) is a rare hereditary multisystem
vascular disorder causing visceral arteriovenous malformations and mucocutaneous …